Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Nine-month period ended 30 September 2014 results press release
Thu, 06/11/2014 - 16:45
0 min
2014 noticia 1.png
Download related document
Select rating
Give Nine-month period ended 30 September 2014 results press release 1/5
Give Nine-month period ended 30 September 2014 results press release 2/5
Give Nine-month period ended 30 September 2014 results press release 3/5
Give Nine-month period ended 30 September 2014 results press release 4/5
Give Nine-month period ended 30 September 2014 results press release 5/5
No votes yet
Related
ROVI increases its operating revenue by 21% and EBITDA by 99%
Operating revenue increased by 21% to 177.5 million euros in the first half of 2019, mainly driven by the strength of the specialty...
6 min
30/07/2019
First half 2019 results presentation
0 min
30/07/2019
ROVI announces completion of the Clinical Trial Program that will support the...
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the conclusion of the PRISMA-3 and BORIS studies, thus...
5 min
05/07/2019
See More
Email
Facebook
Twitter
LinkedIn
2014 noticia 1.png